Distributed Bio, Inc. Sustainability Profile
Distributed Bio, Inc., headquartered in the United States, is a pioneering biotechnology firm specialising in the development of advanced therapeutic antibodies. Founded in 2012, the company has made significant strides in the biopharmaceutical industry, focusing on innovative solutions for infectious diseases and cancer treatment. With a robust portfolio of proprietary technologies, Distributed Bio offers unique services in antibody discovery and optimisation, leveraging its state-of-the-art platforms to enhance therapeutic efficacy. The company has established a strong market position, recognised for its contributions to the field and collaborations with leading pharmaceutical partners. As a key player in the biotechnology landscape, Distributed Bio continues to push the boundaries of antibody engineering, aiming to deliver transformative therapies that address unmet medical needs.
DitchCarbon Score
How does Distributed Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Distributed Bio, Inc.'s score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Distributed Bio, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Charles River Laboratories International, Inc., which may influence its climate commitments and reporting practices. As part of its corporate family, Distributed Bio, Inc. aligns with the sustainability initiatives and climate strategies set forth by Charles River Laboratories. This includes participation in various climate-related initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 commitment to renewable energy. However, specific reduction targets or achievements for Distributed Bio, Inc. have not been disclosed. In summary, while there is no direct emissions data available for Distributed Bio, Inc., its climate commitments are likely informed by the broader sustainability framework established by its parent company, Charles River Laboratories International, Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Distributed Bio, Inc.'s Industry?
How Carbon Intensive is Distributed Bio, Inc.'s Location?
Distributed Bio, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Distributed Bio, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
